Literature DB >> 26475252

Variability of clinical target volume delineation for definitive radiotherapy in cervix cancer.

Gemma Eminowicz1, Mary McCormack2.   

Abstract

BACKGROUND/
PURPOSE: Accurate target volume delineation is essential for radiotherapy delivery, yet significant intra and inter-observer variability is documented. We analysed the variation in cervical cancer clinical target volume (CTV) delineation. MATERIALS/
METHODS: All INTERLACE participating centres completed two RTQA outlining exercises. The Trial Management Group created a consensus outline. A separate STAPLE algorithm outline was created. Using these two outlines an optimised gold standard was generated. Volume, maximum distance from DICOM centre in all directions, and Jaccard Conformity Index (JCI) were calculated and compared for each centres' outlines. Anatomical areas included within CTV were recorded to detect systematic differences.
RESULTS: 21 outlines were compared for case 1 and 22 for case 2. Volume ranged from 340 cc to 676 cc (case 1) and from 458 cc to 806 cc (case 2). A maximum 4 cm difference between outlines was observed in one direction. JCI ranged from 0.51 to 0.81 (case 1) and 0.57 to 0.81 (case 2). Variation in anatomical areas included in CTV exists between the two cases and between centres.
CONCLUSIONS: Significant inter-observer variation in cervical cancer delineation has been demonstrated. Ongoing efforts are needed to ensure inter-observer consistency through education, guidelines and multi-centre collaboration.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cervical cancer radiotherapy; Inter-observer variation; Radiotherapy delineation

Mesh:

Year:  2015        PMID: 26475252     DOI: 10.1016/j.radonc.2015.10.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

Review 1.  Towards precision medicine: from quantitative imaging to radiomics.

Authors:  U Rajendra Acharya; Yuki Hagiwara; Vidya K Sudarshan; Wai Yee Chan; Kwan Hoong Ng
Journal:  J Zhejiang Univ Sci B       Date:  2018 Jan.       Impact factor: 3.066

2.  Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy.

Authors:  François Lucia; Dimitris Visvikis; Marie-Charlotte Desseroit; Omar Miranda; Jean-Pierre Malhaire; Philippe Robin; Olivier Pradier; Mathieu Hatt; Ulrike Schick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-09       Impact factor: 9.236

Review 3.  Review of Radiomics- and Dosiomics-based Predicting Models for Rectal Cancer.

Authors:  Yun Qin; Li-Hua Zhu; Wei Zhao; Jun-Jie Wang; Hao Wang
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

4.  RefineNet-based 2D and 3D automatic segmentations for clinical target volume and organs at risks for patients with cervical cancer in postoperative radiotherapy.

Authors:  Chengjian Xiao; Juebin Jin; Jinling Yi; Ce Han; Yongqiang Zhou; Yao Ai; Congying Xie; Xiance Jin
Journal:  J Appl Clin Med Phys       Date:  2022-05-09       Impact factor: 2.243

5.  Impact of dosimetric differences between CT and MRI derived target volumes for external beam cervical cancer radiotherapy.

Authors:  Vikneswary Batumalai; Siobhan Burke; Dale Roach; Karen Lim; Glen Dinsdale; Michael Jameson; Cesar Ochoa; Jacqueline Veera; Lois Holloway; Shalini Vinod
Journal:  Br J Radiol       Date:  2020-06-18       Impact factor: 3.039

6.  Variability in spine radiosurgery treatment planning - results of an international multi-institutional study.

Authors:  André Toussaint; Anne Richter; Frederick Mantel; John C Flickinger; Inga Siiner Grills; Neelam Tyagi; Arjun Sahgal; Daniel Letourneau; Jason P Sheehan; David J Schlesinger; Peter Carlos Gerszten; Matthias Guckenberger
Journal:  Radiat Oncol       Date:  2016-04-18       Impact factor: 3.481

7.  Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run.

Authors:  Eva Versteijne; Eelco Lens; Astrid van der Horst; Arjan Bel; Jorrit Visser; Cornelis J A Punt; Mustafa Suker; Casper H J van Eijck; Geertjan van Tienhoven
Journal:  Strahlenther Onkol       Date:  2017-06-12       Impact factor: 3.621

8.  Variability in target delineation of cervical carcinoma: A Korean radiation oncology group study (KROG 15-06).

Authors:  Ji Hyeon Joo; Young Seok Kim; Byung Chul Cho; Chi Young Jeong; Won Park; Hak Jae Kim; Won Sup Yoon; Mee Sun Yoon; Ji-Yoon Kim; Jin Hwa Choi; Youngmin Choi; Joo-Young Kim
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

Review 9.  The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.

Authors:  Richard Pötter; Kari Tanderup; Christian Kirisits; Astrid de Leeuw; Kathrin Kirchheiner; Remi Nout; Li Tee Tan; Christine Haie-Meder; Umesh Mahantshetty; Barbara Segedin; Peter Hoskin; Kjersti Bruheim; Bhavana Rai; Fleur Huang; Erik Van Limbergen; Max Schmid; Nicole Nesvacil; Alina Sturdza; Lars Fokdal; Nina Boje Kibsgaard Jensen; Dietmar Georg; Marianne Assenholt; Yvette Seppenwoolde; Christel Nomden; Israel Fortin; Supriya Chopra; Uulke van der Heide; Tamara Rumpold; Jacob Christian Lindegaard; Ina Jürgenliemk-Schulz
Journal:  Clin Transl Radiat Oncol       Date:  2018-01-11

10.  Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China.

Authors:  Yuan Tian; Zefen Xiao; Xiao Chang; Wei Deng; Xin Wang; Zongmei Zhou; Jun Yang; Wenling Guo; Miaoling Liu; Xiaolu Qi; Ling Li; Kaixian Zhang; Min Zhang; Yonggang Shi; Ke Liu; Yidian Zhao; Huitao Wang; Zhilong Yu; Jihong Zhang; Lihua Wang; Xueying Qiao; Chun Han; Shuchai Zhu; Ruohui Zhang; Junqiang Chen; Cairong Hu; Fuquan Zhang; Xiaorong Hou; Qingsong Pang; Wencheng Zhang; Gaofeng Li; Hailei Lin; Xinchen Sun; Xiaolin Ge; Caihong Li; Hong Ge; Dingjie Li; Yadi Wang; Na Lu; Xianshu Gao; Shangbin Qin
Journal:  Radiat Oncol       Date:  2021-06-09       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.